GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » E10

MTNB (Matinas BioPharma Holdings) E10 : $-10.39 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Matinas BioPharma Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.850. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-10.39 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-15), Matinas BioPharma Holdings's current stock price is $0.549. Matinas BioPharma Holdings's E10 for the quarter that ended in Sep. 2024 was $-10.39. Matinas BioPharma Holdings's Shiller PE Ratio of today is .


Matinas BioPharma Holdings E10 Historical Data

The historical data trend for Matinas BioPharma Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings E10 Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -11.04 -11.23

Matinas BioPharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.50 -11.23 -11.14 -10.81 -10.39

Competitive Comparison of Matinas BioPharma Holdings's E10

For the Biotechnology subindustry, Matinas BioPharma Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Shiller PE Ratio falls into.



Matinas BioPharma Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Matinas BioPharma Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.85/133.0289*133.0289
=-0.850

Current CPI (Sep. 2024) = 133.0289.

Matinas BioPharma Holdings Quarterly Data

per share eps CPI Adj_EPS
201412 -5.000 99.070 -6.714
201503 -3.500 99.621 -4.674
201506 -2.000 100.684 -2.643
201509 -2.000 100.392 -2.650
201512 -2.000 99.792 -2.666
201603 -2.000 100.470 -2.648
201606 -1.500 101.688 -1.962
201609 -5.500 101.861 -7.183
201612 -1.500 101.863 -1.959
201703 -12.500 102.862 -16.166
201706 -2.000 103.349 -2.574
201709 -2.000 104.136 -2.555
201712 -2.000 104.011 -2.558
201803 -2.500 105.290 -3.159
201806 -2.000 106.317 -2.503
201809 -1.500 106.507 -1.874
201812 -1.500 105.998 -1.883
201903 -2.000 107.251 -2.481
201906 -1.500 108.070 -1.846
201909 -1.500 108.329 -1.842
201912 -2.000 108.420 -2.454
202003 -1.500 108.902 -1.832
202006 -1.500 108.767 -1.835
202009 -1.500 109.815 -1.817
202012 -1.500 109.897 -1.816
202103 -1.500 111.754 -1.786
202106 -1.000 114.631 -1.160
202109 -1.500 115.734 -1.724
202112 -1.500 117.630 -1.696
202203 -1.500 121.301 -1.645
202206 -1.500 125.017 -1.596
202209 -1.500 125.227 -1.593
202212 -1.000 125.222 -1.062
202303 -1.500 127.348 -1.567
202306 -1.500 128.729 -1.550
202309 -1.390 129.860 -1.424
202312 -1.440 129.419 -1.480
202403 -1.500 131.776 -1.514
202406 -1.000 132.554 -1.004
202409 -0.850 133.029 -0.850

Add all the adjusted EPS together and divide 10 will get our e10.


Matinas BioPharma Holdings  (AMEX:MTNB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Matinas BioPharma Holdings E10 Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings Business Description

Traded in Other Exchanges
N/A
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Executives
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Roelof Rongen director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921